基因变异对结肠直肠癌风险的影响:一项病例对照研究
Zimo Yan1, Xianlei Zhou2, Wenlong Wu1
1College of Life Sciences, North China University of Science and Technology, Tangshan, China.
DNA and cell biology
|March 4, 2026
概括
这种FTO rs9930506基因变异与患结直肠癌 (CRC) 的风险较低有关. 这种保护作用在非吸烟者和非饮酒者中被观察到,这表明它有可能成为CRC敏感性标记物.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 脂肪质量和与肥胖相关的 (FTO) 基因在代谢调节中起作用.
- 在FTO的遗传变异已经涉及到各种疾病,包括癌症.
- 了解FTO变体与结直肠癌 (CRC) 风险之间的关联对于风险分层和预防策略至关重要.
研究的目的:
- 研究FTO遗传变异 (rs9930506和rs9940128) 与结直肠癌 (CRC) 风险之间的关联.
- 与正常组织相比,分析CRC组织中的FTO基因表达.
- 探索已识别的FTO变异对基因表达的调控效应.
主要方法:
- 追溯病例控制研究涉及870个CRC病例和870个匹配的对照.
- 使用PCR-RFLP进行基因型鉴定.
- 使用UALCAN (TCGA) 进行基因表达和GTEx数据用于调节效应的生物信息学分析.
- 无条件后勤回归用于关联分析,对共变量进行调整.
主要成果:
- 在结肠癌组织中FTO表达升高 (p=0.043) 但在直肠癌组织中没有升高 (p=0.250).
- 在多种遗传模型中,FTO变异rs9930506 (A>G) 与降低CRC风险显著相关 (例如,GG与AA:OR=0.30,p<0.001).
- 在非吸烟者和非饮酒者中,rs9930506的保护作用是一致的;rs9940128与CRC风险没有显著关联.
结论:
- 在研究的人群中,FTO rs9930506多态性与结直肠癌的风险降低有关.
- FTO rs9930506可以作为结直肠癌的潜在敏感性标记物.
- 需要进一步的研究来阐明FTO在CRC病变发生过程中的作用的确切机制.
相关概念视频
Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


